logo

For the Inventor, By the Inventor

Riverdale, NY, United States of America

Michael J Yellin

USPTO Granted Patents = 12

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 106(Granted Patents)


Company Filing History:

goldMedal12 out of 2,488 
 
Columbia University
 patents

Years Active: 1995-2006

Loading Chart...
12 patents (USPTO):Explore Patents
1. 7070777 - Method for inhibiting inflammation with an antibody that binds the 5C8 protein (2006-07-04),
2. 6793924 - Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8. (2004-09-21),
3. 6610294 - Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds (2003-08-26),
4. 6592868 - Methods for treating autoimmune diseases with 5C8-specific antibodies (2003-07-15),
5. 6455044 - 5c8 antigen (2002-09-24),
6. 6451310 - Method for inhibiting an allergic response with a 5c8-specific antibody (2002-09-17),
7. 6403091 - Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies (2002-06-11),
8. 6340459 - Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients (2002-01-22),
9. 6331615 - Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) (2001-12-18),
10. 6331433 - Human T cell leukemia cell line designated D1.1 (2001-12-18),
11. 5993816 - Methods to inhibit humoral immune responses, immunoglobulin production (1999-11-30),
12. 5474771 - Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the (1995-12-12),

Title: Innovative Contributions of Michael J. Yellin

Introduction: Michael J. Yellin, based in Riverdale, NY, is a remarkable inventor with a significant portfolio comprising 12 patents. His work primarily focuses on medical advancements, particularly in the field of inflammation and antibody research.

Latest Patents: Among his latest patents, Yellin has developed a method for inhibiting inflammation using an antibody that binds the 5C8 protein. This groundbreaking invention outlines methods for utilizing antibodies to effectively reduce inflammation by targeting this specific protein. Additionally, he has introduced a protein free of cell membranes and other cellular components, recognized specifically by the monoclonal antibody 5C8 produced by the hybridoma with ATCC Accession No. HB 10916. This invention emphasizes its utility in medical applications by highlighting a protein fragment that retains the essential epitope specifically bound by monoclonal antibody 5C8. His latest work further refines this concept, offering proteins that are substantially composed of epitopes crucial for targeted therapeutic interventions.

Career Highlights: Yellin has made significant strides in his career through his tenure at Columbia University. His dedication to innovation in medical research has led to the successful patenting of multiple techniques that pave the way for advanced treatments and therapeutics.

Collaborations: Collaborating with eminent colleagues such as Seth Lederman and Leonard Chess, Yellin has been a part of impactful research initiatives. These partnerships not only enhance the breadth of his inventive endeavors but also foster innovation within his field, leading to breakthroughs that have the potential to improve patient outcomes.

Conclusion: Michael J. Yellin's contributions to the field of medicine through his inventive prowess exemplify the essence of innovation. His patents reflect a commitment to enhancing healthcare and addressing critical medical challenges, marking him as a key figure in the world of scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…